Defence Therapeutics【DTC】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.43

買値

1.38

売値

1.48

出来高

497,250

1.30 日の範囲 1.47

0.48 52 週間の範囲 2.10

前日終値

1.25

始値

1.30

時刻

100

1.43

最終取引時間

平均取引量 (3 か月)

57,069

財務取引量

VWAP

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC:...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.33	30	1.1	1.47	1.08	100938	1.17831902	CS
4	0.73	104.285714286	0.7	1.47	0.7	116105	1.06445959	CS
12	0.89	164.814814815	0.54	1.47	0.49	57069	0.91489242	CS
26	0.76	113.432835821	0.67	1.47	0.48	39467	0.79827171	CS
52	-0.52	-26.6666666667	1.95	2.1	0.48	37349	0.96406345	CS
156	-3.06	-68.1514476615	4.49	4.85	0.48	22784	1.872751	CS
260	-0.32	-18.2857142857	1.75	8.15	0.48	20743	2.32453424	CS

DTC - Frequently Asked Questions (FAQ)

What is the current Defence Therapeutics share price?

The current share price of Defence Therapeutics is $ 1.43

What is the 1 year trading range for Defence Therapeutics share price?

Defence Therapeutics has traded in the range of $ 0.48 to $ 2.10 during the past year

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
ETIEnviroMetal Technologies Inc	$ 0.01 (100.00%)	119k
FFF55 North Mining Inc	$ 0.01 (100.00%)	15k
ASTIAquarius Surgical Technologies Inc	$ 0.02 (100.00%)	5k
CACR.AKWG Resources Inc	$ 2.34 (80.00%)	100
USLIAmerican Salars Lithium Inc	$ 0.12 (71.43%)	1.23M
TGLDTorrent Gold Inc	$ 0.035 (-58.82%)	4.23k
AWRAurwest Resources Corporation	$ 0.005 (-50.00%)	11k
MJRXGlobal Health Clinics Ltd	$ 0.01 (-50.00%)	201.39k
CHGXChitogenX Inc	$ 0.005 (-50.00%)	235k
CCRGreen River Gold Corp	$ 0.005 (-50.00%)	340k
QIMCQuebec Innovative Materials Corp	$ 0.215 (-6.52%)	4.58M
SYAISyntheia Corp	$ 0.18 (28.57%)	2.82M
GRUVProtium Clean Energy Corp	$ 0.035 (0.00%)	2.3M
SOLSOL Global Investments Corp	$ 0.295 (-15.71%)	1.96M
AIMLAl ML Innovations Inc	$ 0.07 (16.67%)	1.64M

Man6677 3年前

Why are there no trades here ?

Thank you !

Great news today !

👍️0

newspopper 3年前

Get in KITL .08-.10 news will be poppin

👍️0

newspopper 3年前

Need more volume for Poppin action

👍️0

newspopper 3年前

Looking for FDA Poppin news

👍️0

newspopper 3年前

KITL news going to be poppin

👍️0

GOLDBUFFALO 3年前

Seems to be a very interesting stock.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Defence Therapeutics Inc (DTC)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

DTC 最新ニュース

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

DTC - Frequently Asked Questions (FAQ)

ムーバー

DTC Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Defence Therapeutics Inc (DTC) 銘柄情報

Defence Therapeutics Inc (DTC)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

DTC 最新ニュース

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

DTC - Frequently Asked Questions (FAQ)

ムーバー

DTC Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する